CUI Bing
Principal Investigator
Education
09/1996-07/2001: B.S., China Pharmaceutical University, Pharmacology
09/2001-07/2004: M.S., China Pharmaceutical University, Cardiovascular Pharmacology
09/2004-07/2007: Ph.D., Peking Union Medical College, Molecular Pharmacology
Professional experiences
2007-2012 Postdoctoral fellow, Dr. Thomas J. Kipps lab, Division of Hematology-Oncology, Moores Cancer Center, University of California, San Diego, USA.
2012-2015 Assistant project scientist, Division of Hematology-Oncology, Moores Cancer Center, University of California, San Diego, USA.
2015-present Principal investigator, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College.
Research Interests
Cui Bing's research is primarily directed towards understanding cellular and molecular mechanism of cancer and fibrotic diseases. He is focusing his attention on the molecular mechanism and drug target identification of cancer metastasis and tumor stemness, the biology of cancer stem cells and microRNA, and drug identification for metabolic disorder related diseases.
1. TRIB3 Supports Breast Cancer Stemness by Suppressing FOXO1 Degradation and Enhancing SOX2 Transcription. Nat Commun 2019;10(1):5720.
2. Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting. Acta Pharm Sin B 2019; 9(5):960-972.
3. Highlights of the 2nd International Symposium on Tribbles and Diseases: Tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer. Acta Pharm Sin B 2019;9(2):443-454.
4. Regulation of immune-related diseases by multiple factors: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences Initiative for Innovative Medicine on Tumor Immunology. Acta Pharmaceutica Sinica B 2017, 7(4):532-540.
5. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood 2016, 128(25):2931-2940.
6. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A 2014,111(48):17266-71.
7. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 2014, 124(4):546-54.
8. ROR1 Can Interact With TCL1 And Enhance Leukemogenesis in Eµ-TCL1 Transgenic Mice. Proc Natl Acad Sci U S A 2014, 111(2):793-798.
9. Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis. Cancer Research 2013,73(12):3649-60.
10. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol. 2009,182(1):692-702.
11. Disrupting the TRIB3-SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome-mediated HSC activation. Autophagy. 2020,16(5):782-796.
12. Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell. 2018, 33(3):480-494.e7
13. Wnt5a Induces ROR1 to Complex with HS1 to Enhance Migration of Chronic Lymphocytic Leukemia Cells. Leukemia, 2017, 31(12):2615-2622.
14. Cirmtuzumab Inhibits Wnt5a-Induced Rac1 activation In Chronic Lymphocytic Leukemia Treated With Ibrutinib. Leukemia, 2017,31(6):1333-13339.
15. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence. Cancer Cell. 2017 May;31(5):697-710.
16. Hematopoietic-derived Galectin-3 Causes Cellular and Systemic Insulin Resistance. Cell. 2016,167(4):973-984.e12.
17. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016,126(2):585-98.
18. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 2014,124(10):1637-44.
19. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A. 2013 Apr;110(15):6127-32.
20. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013 Feb;121(6):971-4.
1. Autophagy: Biology and Disease (Basic Science). Cui B, Lin H, Yu JM, Yu JJ, Hu ZW. ed.Qin Zheng-Hong. Science Press, Autophagy and Immune Response (Chapter 27, 595-634), Dec 2019. ISBN: 978-981-15-0602-4.
2. Basic of Organ Fibrosis and Treatment with Traditional Chinese Medicine. Hu ZW, Cui B and Yang HZ. ed. Niu JianZhao，Pen ChangEn. People's Medical Publishing House. Immune Mechanism of Fibrosis Disease (Chapter 6, page 171-201) . Jan 2008, ISBN: 9787117093378 (Chinese).
3. Basic of Organ Fibrosis and Treatment with Traditional Chinese Medicine. Hu ZW, Cui B and Wang XX. ed. Niu JianZhao, Pen ChangEn. People's Medical Publishing House. Pancreatic Fibrosis (Chapter 10, page 399-428) . Jan 2008, ISBN: 9787117093378 (Chinese).
4. Basic of Organ Fibrosis and Treatment with Traditional Chinese Medicine. Yan HM, Pen CE, and Cui B. ed. Niu JianZhao，Pen ChangEn. People's Medical Publishing House. Methods for Measuring Hydroxyproline and Collagen (Chapter 23, page 635-649). Jan 2008, ISBN: 9787117093378 (Chinese).
5. Current Pharmacological Experimental Methods, Second Edition, Hu ZW, Cui B, Yang HZ. ed. Zhang JT. Chinese Academy of Medical Sciences & Peking Union Medical College Press. Overview of Experimental Methods for Tissue Fibrosis (Chapter 1, page 1925-1939). Aug 2012, ISBN: 9787811363753 (Chinese).
6. Current Pharmacological Experimental Methods, Second Edition, Cui B, Yan HM, Hu ZW ed. Zhang JT. Chinese Academy of Medical Sciences & Peking Union Medical College Press. Pharmacological Experimental Methods for Pulmonary Fibrosis (Chapter 12, page 1964-1969). Aug 2012, ISBN: 9787811363753 (Chinese).
7. Current Pharmacological Experimental Methods, Second Edition, Yan HM, Cui B, Xin BM, Hu ZW ed. Zhang JT. Chinese Academy of Medical Sciences & Peking Union Medical College Press. Methods for Measuring Hydroxyproline and Collagen in (Chapter 12, page 2058-2069) . Aug 2012, ISBN: 9787811363753 (Chinese).
2016, Natural Science Achievement Award from Ministry of Education, Second Prize, China.
2013, AACR-Millennium Scholar-in-Training Awards, 104th AACR Annual Meeting, USA.
2000, National First Prize of National College Mathematical Modeling Contest, China.
